Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + axitinib
- Development stage
- Phase 2
- Lead developer
- Innovent Biologics Technology Limited (Shanghai R&D Center)
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Combination therapy consisting of sintilimab, a fully recombinant human IgG4 anti-PD-1 monoclonal antibody, and axitinib, a second-generation tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3). Sintilimab works by binding to PD-1, blocking its interaction with PD-L1 and PD-L2, thereby restoring the endogenous antitumor T-cell response. Axitinib prevents angiogenesis and blocks tumor growth by inhibiting VEGFR signaling. This combination has shown promising efficacy in various types of renal cell carcinoma, including advanced fumarate hydratase-deficient renal cell carcinoma (FH-dRCC), locally advanced renal cell carcinoma, and metastatic chromophobe renal cell carcinoma (ChRCC).
- Other names
- Sintilimab injection plus Inlyta treatmentSintilimab plus Axitinib
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)
Beyond the preview
Go deeper on sintilimab + axitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + axitinib.